27,722 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 27,722 shares of the company’s stock, valued at approximately $611,000.

Other large investors also recently bought and sold shares of the company. Royal Bank of Canada raised its stake in shares of Teva Pharmaceutical Industries by 17.2% in the 4th quarter. Royal Bank of Canada now owns 1,177,603 shares of the company’s stock valued at $25,954,000 after acquiring an additional 173,050 shares during the period. Raiffeisen Bank International AG acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth $183,000. Quantinno Capital Management LP lifted its stake in Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Quantinno Capital Management LP now owns 43,097 shares of the company’s stock worth $950,000 after acquiring an additional 6,952 shares in the last quarter. Man Group plc lifted its position in shares of Teva Pharmaceutical Industries by 191.7% during the fourth quarter. Man Group plc now owns 43,302 shares of the company’s stock worth $954,000 after purchasing an additional 28,457 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV lifted its holdings in Teva Pharmaceutical Industries by 1.1% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 139,049 shares of the company’s stock worth $3,166,000 after buying an additional 1,575 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TEVA shares. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Finally, UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and an average target price of $24.43.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $16.95 on Friday. The company has a market cap of $19.22 billion, a P/E ratio of -11.69, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The business has a fifty day moving average of $15.35 and a two-hundred day moving average of $17.41. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.48 earnings per share. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.